NASDAQ$LENZ
LENZ Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
LENZ Therapeutics Inc Q1 fiscal 2026: $1.90B revenue, $41.5M net loss
LENZ Therapeutics Inc net loss per share, basic and diluted $ ( 1. (SEC accession 0001815776-26-000037)
- Revenue: $1.90B
- Net loss: $41.5M
- Diluted EPS: $-1.32
- Operating income: $-44.1M
Headline financials
Revenue & EPS history
LENZ Therapeutics Inc · Revenue · Quarterly
$1.9M
Q1 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 9 quarterly earnings reports · overlaid with Q1 2026
-2.7%
Avg return
Earnings day
-3.8%
Avg return
5 days after
-0.9%
Avg return
30 days after
30%
3 / 10 earnings
Positive
+5.0%
Q2 2022
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -27.1% | — | |
| Q4 2025 | +0.4% | -8.2% | +3.9% | |
| Q3 2025 | -23.5% | -17.3% | -4.7% | |
| Q2 2025 | -2.9% | -7.4% | +22.0% | |
| Q3 2023 | -1.7% | -0.4% | -1.3% | |
| Q2 2023 | -4.5% | -4.5% | -17.4% | |
| Q1 2023 | -0.3% | -3.2% | -8.4% | |
| Q3 2022 | +1.9% | +7.1% | +1.9% | |
| Q2 2022 | +5.0% | +9.3% | -9.0% | |
| Q1 2022 | -0.9% | +13.9% | +5.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro